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 Previously regarded as an innocuous commensal 
microorganism on the human skin, Staphylococcus 
epidermidis is now seen as an important opportunistic 
pathogen1-3. This bacterium has become the leading 
cause of infections related to indwelling medical 
devices such as vascular catheters, prosthetic joints and 
artificial heart valves, mainly due to its capacity to form 
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Background & objectives: Staphylococcus epidermidis is the most common pathogen associated with 
infections of surgical implants and other prosthetic devices owing to its adhesion and biofilm-forming 
ability on biomaterials surfaces. The objective of this study was to compare susceptibilities of biofilm-
grown cells to single antibiotic and in combination with others to identify those that were effective against 
S. epidermidis biofilms. 
Methods: Biofilms were grown in the MBEC™ assay system. The use of this methodology allowed a 
rapid testing of an array of antibiotics alone (eight) and in combination (25 double combinations). The 
antibacterial effect of all treatments tested was determined by colony forming units (cfu) enumeration 
method.
Results: The MBEC™ assay system produced multiple and reproducible biofilms of S. epidermidis. 
Although none of the antibiotics tested have demonstrated an antimicrobial effect (log reduction >3) 
against all S. epidermidis isolates biofilms, but combinations containing rifampicin showed in general 
a broader spectrum namely rifampicin-gentamicin and rifampicin-clindamycin. Levofloxacin in 
combination with rifampicin showed a killing effect against three isolates but failed to attain a bactericidal 
action against the other two. 
Interpretation & conclusions: Our findings showed that rifampicin should be a part of any antibiotic 
therapy directed against S. epidermidis biofilms. However, the efficient antibiotics combination might be 
dependent on S. epidermidis isolate being tested.
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biofilms on such materials thus causing persistent or 
recurrent infections4,5. Infections of medical implants 
material are associated with considerable morbidity and 
costs4. These infections are very difficult to eradicate 
since bacteria in biofilms can be up to 1,000-fold more 
resistant to antibiotic treatment than the same organism 
growing planktonically6-8. Another problem is the ability 
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of bacteria to acquire resistance to antibiotics therapy. 
This arises from the frequent use of antibiotics and 
mainly those of broad-spectrum. Only a few antibiotics 
are relatively active against S. epidermidis biofilms, 
and rifampicin, a transcription inhibitor, is among the 
most effective molecules for treating biofilm-related 
infections9. However, in a study where the prevalence 
of drug resistance among clinically significant blood 
isolates of S. epidermidis (n = 464) and consumption of 
antibiotics at a tertiary care teaching hospital (Meilahti 
Hospital, Helsinki) were analysed for the period 1983-
1994, a remarkable increase was found in resistance to 
rifampin (from 0 to 23%) despite the low usage of this 
agent10. Accordingly, since rifampicin demonstrated a 
high risk of rapid development of resistance, it should 
not be used as monotherapy1.
 Taking this fact into account, antibiotic 
combinations are often necessary in the treatment of 
S. epidermidis infections and these combinations are 
used involving antibiotics like rifampicin to avoid the 
appearance of antimicrobial resistance1,11. Moreover, 
the combinations can also enhance the effects of 
individual antimicrobial agents by synergic action. 
Another alternative to overcome the resistance problem 
in Staphylococci is the use of novel antibiotics such 
as linezolid, daptomycin, tigecycline and quinupristin/
dalfopristin that have been developed and claimed to be 
100 per cent efficient12. Some of the newer antimicrobial 
agents may provide alternatives for monotherapy or 
combination therapy with rifampicin1. However, this 
new antibiotic generation is very expensive, so the use 
of conventional antibiotics or antibiotic combinations 
still represents a valid therapeutic option. 
 The aim of the present work was to investigate the 
antimicrobial activity of some of the most common 
antibiotics alone and in combination against in vitro S. 
epidermidis biofilms.
Material & Methods
Bacterial isolates & antibiotics: In this study, previously 
well characterized biofilm-producing S. epidermidis 
isolates were used: 117977, 132034, 150571, 1457 and 
9142. The first three were obtained from the Department 
of Biological Sciences, University of Calgary, Calgary, 
Canada and the last two were provided by Dr G.B. 
Pier, Channing Laboratory, Department of Medicine, 
Brigham and Women’s Hospital, Harvard Medical 
School, Boston, USA. These were clinical isolates 
(isolated from infected catheters) and were stored at 
-80ºC. All the assays were performed using brain heart 
infusion (BHI) medium, tryptic soy broth (TSB) and 
tryptic soy agar (TSA) [Merck, Germany], prepared 
according to the manufacturer’s instructions. This 
study was done in Ceri lab, Department of Biological 
Sciences, University of Calgary, Calgary, Alberta, 
Canada.
 Antibiotics tested were vancomycin, tetracycline, 
rifampicin, gentamicin, cefazolin, cephalotin, 
levofloxacin and clindamycin. All antibiotics were 
purchased from Sigma Chem. Co., USA. The 
concentrations used to test the susceptibility of 
biofilm-grown S. epidermidis to single and double-
combinations of antibiotics are presented in Table I.
Biofilm formation: Biofilms were grown in a Calgary 
biofilm device (CBD) [commercially available as the 
MBEC physiology and genetics assay (Innovotech 
Inc., Edmonton, AB, Canada)], as originally described 
by Ceri et al14. The CBD consists of two-part reaction 
vessel. The top component of the device is a polystyrene 
lid with 96 identical pegs. The lid is inserted into the 
bottom piece of the device- a microtiter plate into which 
the inoculated growth medium is placed. The CBD is 
then placed on a gyro rotary shaker in an incubator 
which provides a shear force against the pegs, this 
facilitates the formation of 96 statistically equivalent 
biofilms on the surface of the pegs14-16. 
 In brief, several colonies of the isolates grown on 
TSA plates were suspended in saline (0.9% NaCl) to 
a density of 1.0 on the McFarland scale, as indicated 
by the manufacturer. The bacterial suspension was 
resuspended in medium to obtain a cellular concentration 
of circa 1 × 107 colony forming units (cfu)/ml. This 
solution was used as inoculum for the MBECTM 




Vancomycin 4 8-16 32
Tetracycline 4 8 16
Rifampicin 1 2 4
Gentamicin 4 8 16
Cefazolin 8 16 32
Cephalothin 8 16 32
Levofloxacin 1 2 4
Clindamycin 0.5 - 2
*Concentration used in single, double-combination antibiotic 
susceptibility testing
Source: Ref. 13
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device (MBECTM Biofilm Technologies Ltd. Calgary, 
Alberta, Canada). The biofilms were grown during 48 
h, at 37ºC at 150 rpm and on a rocking platform where 
the shear force was created against the pegs forming 
96 equivalent biofilms. To enumerate the biofilm cfu 
on individual control pegs, pegs were broken off the 
MBEC peg lid using sterile forceps, placed into 200 µl 
of sterile saline and sonicated for 8 min. Bacteria were 
then enumerated by serial dilution plating. Colony 
forming units/peg counts were determined from at 
least three independent experiments. 
 This protocol was performed with three different 
biofilm growth media: TSB, TSB + 0.25% glucose and 
BHI medium. After selecting the medium that allowed 
the highest biofilm formation (cfu per peg >6 log), 
the previous procedure was repeated with the selected 
medium.
Biofilm challenge and recovery: The challenge plates 
were prepared using the antibiotics at break-point 
concentrations (Table I) alone and in all possible double 
combinations (Table II). The biofilms formed on the lid 
of the MBECTM were rinsed twice with 0.9 per cent 
saline and placed into the challenge plate overnight at 
37ºC, at 150 rpm, on a rocking platform and 95 per cent 
relative humidity. After that the challenged biofilms 
were rinsed twice in saline and were tranferred to a 
recovery plate that consisted of TSB medium plus (1% 
v/v) Tween 80. Biofilms were removed from all pegs at 
once, by sonication for 8 min on high with an Aquasonic 
sonicator (model 250HT, VWR Scientific, Mississauga, 
ON, Canada)14. The vibration disrupted biofilms from 
the surface of the 96 pegs into the recovery plate. Then, 
colony forming units were determined as follows: the 
recovery medium (containing the sonicated biofilms) 
was serially diluted. The biofilm cultures (10-fold 
diluted) were spotted on TSA plates, the plates were 
incubated for 48 h at 37ºC to ensure maximum recovery 
of the surviving microorganisms and after that the cfu 
counted. 
Results
 In this study, eight antibiotics, commonly used 
in the treatment of Gram-positive infections, were 
tested at their breakpoint concentrations. The effect of 
these antibiotics combined in pairs (Table II) was also 
assessed. TSB without glucose stimulated more biofilm 
formation (data not shown), forming at the end of the 
incubation period (48 h), a biofilm of approximately 
6 log cfu per peg. Thus, this medium was selected 
for the subsequent antibiotic susceptibility tests on S. 
epidermidis biofilms. The amount of glucose (0.25% 
w/v) used to promote the formation of S. epidermidis 
biofilms in traditional 96-well plates6,17 was not 
favourable to biofilm formation in CBD. 
 The effect of the tested antibiotics alone was 
evaluated against the biofilms of the five clinical isolates 
of S. epidermidis assayed. The results obtained are 
expressed as reduction in treated biofilms compared to 
untreated controls (Table III). In general, none of the 
antibiotics tested was effective against S. epidermidis 
Table II. Antibiotics used and combinations tested
Antibiotic Combinations
VANC VANC + RIF TET + CEPH GENT + CEPH
TET VANC + GENT TET + LEVO GENT + LEVO
RIF VANC + CEF TET + CLIND GENT + CLIND
GENT VANC + CEPH RIF + GENT CEF + CEPH
CEF VANC + LEVO RIF + CEF CEF + LEVO
CEPH VANC + CLIND RIF + CEPH CEF + CLIND
LEVO TET + RIF RIF + LEVO CEPH + LEVO
CLIND TET + GENT RIF + CLIND CEPH + CLIND
VANC + TET TET + CEF GENT + CEF LEVO + CLIND
VANC, vancomycin; TET, tetracycline; RIF, rifampicin; GENT, 
gentamicin; CEF, cefazolin; CEPH, cephalothin; LEVO, levofloxacin; 
CLIND, clindamycin
Table III. Viable cell number reduction in 48 h-biofilms, expressed as log10 cfu/ml, after overnight exposure to individual antibiotics
S. epidermidis 
isolate
VANC TET RIF GENT CEF CEPH LEVO CLIND
117977 0.00 ± 0.24 1.20 ± 0.24 2.37 ± 0.68 0.00 ± 0.29 0.00 ± 0.23 0.00 ± 0.29 2.86 ± 0.48 1.68 ± 0.35
132034 0.26 ± 0.73 2.70 ± 0.48 4.01 ± 0.47 0.56 ± 0.30 0.29 ± 0.46 2.39 ± 0.38 0.32 ± 0.19 0.15 ± 0.32
150271 0.36 ± 0.44 0.31 ± 0.40 3.15 ± 0.18 0.14 ± 0.42 0.46 ± 0.36 1.84 ± 0.51 1.87 ± 0.36 2.20 ± 0.32
1457 0.00 ± 0.51 2.02 ± 0.20 1.58 ± 0.22 0.00 ± 0.19 1.63 ± 0.47 2.40 ± 0.31 2.18 ± 0.35 1.72 ± 0.20
9142 0.57 ± 0.53 1.54 ± 0.42 2.42 ± 0.44 0.19 ± 0.38 0.14 ± 0.40 0.26 ± 0.54 3.63 ± 0.12 0.28 ± 0.51
VANC, vancomycin; TET, tetracycline; RIF, rifampicin; GENT, gentamicin; CEF, cefazolin; CEPH, cephalothin; LEVO, levofloxacin; 
CLIND, clindamycin
Values are mean ± standard deviation. (n=4)
biofilm. Only rifampicin was effective against S. 
epidermidis isolates 132034 and 150271 as well as 
levofloxacin against isolate 9142 (Table III) because 
the log10 cfu reduction observed was higher than 3 
log. Although the reduction caused by rifampicin and 
levofloxacin is mostly inferior to 3 log, these were the 
antibiotics having the broadest and highest antimicrobial 
effect against all S. epidermidis isolates tested. 
Table IV. Viable cell number reduction in 48 h-biofilms, expressed as log10 cfu/ml, after overnight exposure to double combinations of 
antibiotics
Isolates VANC + TET VANC + RIF VANC + GENT VANC + CEF
117977 1.33 ± 0.30 2.32 ± 0.36 0.00 ± 0.38 0.00 ± 0.18
132034 2.89 ± 0.49 4.22 ± 0.42 0.58 ± 0.24 0.25 ± 0.36
150271 0.11 ± 0.24 2.91 ± 0.12 0.28 ± 0.28 0.93 ± 0.78
1457 1.89 ± 0.63 2.47 ± 0.60 1.45 ± 0.59 2.21 ± 0.57
9142 1.72 ± 0.17 2.75 ± 0.43 0.47 ± 0.43 0.40 ± 0.37
Isolates VANC + CEPH VANC + LEVO VANC + CLIND TET + RIF
117977 0.00 ± 0.15 2.56 ± 0.38 1.75 ± 0.37 2.49 ± 0.49
132034 1.02 ± 0.40 0.53 ± 0.23 0.26 ± 0.50 3.37 ± 0.43
150271 1.75 + 0.39 2.60 ± 0.35 2.16 ± 0.20 2.03 ± 0.24
1457 2.35 ± 0.44 2.13 ± 0.42 1.24 ± 0.35 2.09 ± 0.49
9142 0.39 ± 0.49 2.50 ± 0.37 0.68 ± 0.29 2.28 ± 0.40
Isolates TET + GENT TET + CEF TET + CEPH TET + LEVO
117977 1.43 ± 0.41 1.29 ± 0.48 1.07 ± 0.31 2.62 ± 0.43
132034 2.77 ± 0.35 2.41 ± 0.26 1.92 ± 0.48 3.14 ± 0.17
150271 0.23 ± 0.35 1.12 ± 0.45 1.78 ± 0.13 2.63 ± 0.15
1457 2.21 ± 0.48 1.84 ± 0.46 1.71 ± 0.83 2.07 ± 0.44
9142 2.01 ± 0.27 1.58 ± 0.49 1.51 ± 0.59 1.81 ± 0.29
Isolates TET + CLIND RIF + GENT RIF + CEF RIF + CEPH
117977 1.72 ± 0.26 2.46 ± 0.63 1.82 ± 0.24 1.76 ± 0.43
132034 2.86 ± 0.51 3.11 ± 0.56 3.45 ± 0.28 3.08 ± 0.32
150271 2.23 ± 0.52 2.49 ± 0.22 2.69 ± 0.45 2.73 ± 0.24
1457 1.96 ± 0.46 2.06 ± 0.16 1.85 ± 0.37 2.11 ± 0.55
9142 1.84 ± 0.18 3.14 ± 0.56 1.90 ± 0.20 1.41 ± 0.69
Isolates RIF + LEVO RIF + CLIND GENT + CEF GENT + CEPH
117977 3.49 ± 0.44 2.65 ± 0.33 0.00 ± 0.44 0.00 ± 0.39
132034 3.18 ± 0.56 3.68 ± 0.23 0.22 ± 0.13 0.79 ± 0.65
150271 2.83 ± 0.21 2.73 ± 0.49 0.06 ± 0.51 1.04 ± 0.42
1457 3.24 ± 0.42 2.46 ± 0.31 2.19 ± 0.35 2.49 ± 0.67
9142 1.71 ± 0.58 2.64 ± 0.27 0.39 ± 0.18 1.03 ± 0.44
Isolates GENT + LEVO GENT + CLIND CEF + CEPH CEF + LEVO
117977 3.76 ± 0.57 1.48 ± 0.31 0.00 ± 0.28 3.90 ± 0.30
132034 0.31 ± 0.37 0.14 ± 0.23 1.03 ± 0.43 0.11 ± 0.42
150271 2.91 ± 0.43 2.15 ± 0.25 1.82 ± 0.24 3.06 ± 0.55
1457 2.28 ± 0.43 1.98 ± 0.49 2.40 ± 0.47 2.55 ± 0.26
9142 1.83 ± 0.24 0.16 ± 0.38 1.92 ± 0.65 2.14 ± 0.58
Isolates CEF + CLIND CEPH + LEVO CEPH + CLIND LEVO + CLIND
117977 1.11 ± 0.25 3.38 ± 0.42 0.86 ± 0.32 2.68 ± 0.28
132034 0.29 ± 0.16 0.64 ± 0.19 0.87 ± 0.61 0.07 ± 0.30
150271 1.50 ± 0.25 2.74 ± 0.16 1.48 ± 0.27 2.54 ± 0.32 
1457 1.44 ± 0.36 2.28 ± 0.50 1.75 ± 0.36 2.25 ± 0.42
9142 0.31 ± 0.43 2.72 ± 0.51 1.13 ± 0.45 2.33 ± 0.61
VANC, vancomycin; TET, tetracycline; RIF, rifampicin; GENT, gentamicin; CEF, cefazolin; CEPH, cephalothin; LEVO, levofloxacin; 
CLIND, clindamycin
Values are mean ± standard deviation. (n=4)
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 The results presented in Table IV show the 
reduction in biofilms log10 cfu for all combinations 
of antibiotics tested. Most combinations tested did 
not promote a 3 log reduction in bacterial counts. 
Nevertheless, and as it could be expected, most of those 
containing rifampicin were able to reach at reasonable 
levels of bactericidal effect. Examples are rifampicin-
clindamycin and rifampicin-gentamicin, the former 
promoting reductions above 2.5 log in biofilm cell 
counts for all isolates tested. Notably, the combination 
rifampicin-levofloxacin displayed a high killing effect 
specifically against three isolates but against 9142 the 
log reduction was below 2.0. 
Discussion
 Standard antibiotic therapy is only able to eliminate 
planktonic cells, leaving the sessile forms to propagate 
within the biofilm and to continue to disseminate 
when therapy is terminated. In biofilms, microbes 
are protected from antimicrobial agents and the host 
immune system18. In fact, increasingly microorganisms 
have the ability to withstanding the effect of antibiotics 
and individual antibiotics are generally ineffective 
against bacteria biofilms. To overcome such problems, 
combination of antibiotics is a possible alternative 
to threat staphylococcal biofilm infections. Previous 
studies have also demonstrated impressive results with 
rifampicin, however, the risk of rapid development 
of resistance is a major problem, and rifampicin 
should not be used as monotherapy1,19,20. It has been 
considered that combinations of rifampicin with other 
anti-staphylococcal agents such as quinolones or 
fusidic acid could prevent the emergence of rifampicin 
resistance during therapy19,21.
 Since antibiotics alone were generally not 
effective against S. epidermidis biofilms and taking 
into consideration the strategy of combined therapy 
to avoid resistance, the double combinations of the 
antibiotics were tested against the same biofilms. 
In a previous study22, where some double and triple 
combinations of antibiotics were studied, several 
triple combinations, all containing rifampicin were 
active against S. epidermidis and only one double 
combination vancomycin - rifampicin was reported to 
be active. In this study, 17 S. epidermidis isolates were 
assessed and the susceptibility to antibiotics was tested 
in terms of minimum inhibitory concentration (MIC) 
and minimum bactericidal concentration (MBC). 
However, a triple combination may be an overload 
of antibiotics and more prone to the development of 
secondary effects. 
 Monzón et al11 also tested some double 
combinations of antibiotics against four S. epidermidis 
isolates and the highest reduction they observed was 
2.19 log obtained with the combination vancomycin-
rifampicin and only against one specific isolate, using 
both antibiotics at 4 x MIC.
 In this study, we tested the effect of traditional 
antibiotics alone and in combination, in S. epidermidis 
biofilm cells, using breakpoint concentrations13,22. The 
Calgary Biofilm Device (CBD) was used for biofilm 
formation because, despite being expensive, it is a 
high-throughput methodology with several advantages, 
namely its multiple equivalent biofilms that can be used 
for testing. Its use can avoid the need to repeat assays, 
which is usually necessary when using standard plates. 
An array of antimicrobial compounds with varying 
concentrations can easily be assessed. This allows 
rapid testing of compounds for antibiofilm activity. 
These advantages can overcome the cost associated 
problems of this methodology. 
 Our results demonstrated the advantage of using 
antibiotic combinations in the treament of S. epidermidis 
infections. However, the effect of these combinations 
is highly strain-dependent. Alternative agents are 
novel antibiotics such as linezolid, tigecycline and 
daptomycin claimed to be highly effective against 
biofilms but these agents have some disadvantages. 
Apart from their high cost, these have been in clinical 
use for a short time only and the extent of their toxicity 
is yet to be experienced. Hajdu et al4 observed no 
significant reduction in S. epidermidis biofilms cfu 
with daptomycin and tigecycline, not even at the 
highest concentrations tested (128 × MIC). Generally 
these concentrations are far beyond any concentration 
that can be achieved after administration of standard 
therapeutic doses4. Aslam et al23 also tested the effect 
of tigecycline and after 12 h of treatment only a mean 
reduction of the bacterial growth by 2log10 counts was 
obtained, notably using a concentration of 1 mg/ml 
(1,000 fold higher than its MIC for the organisms tested 
in the planktonic phase). In this case, the concentration 
of tigecycline expected to be in human serum after 
standard dosing is 2 mg/l4. Utilizing high doses of 
antimicrobials to eradicate biofilm has had limited 
successs in the clinical setting23.
 In conclusion, there are some combinations of more 
traditional antibiotics that can be strongly considered 
as therapeutic strategies for an efficient control of S. 
epidermidis biofilms associated infections. Rifampicin 
combined with clindamycin or with gentamicin showed 
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to have the broadest range of action, although rifampicin 
in combination with levoflxacin displayed a higher 
killing effect against three out of the five isolates. As 
an alternative to monotherapy, these combinations can 
be advantageous avoiding the likehood of resistance 
development.
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